Research Data from Purdue University Update Understanding of Peptide Receptors (Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles)
By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Membrane Proteins have been presented. According to news originating from West Lafayette, Indiana, by NewsRx correspondents, research stated, "In targeted photodynamic therapy (tPDT), photosensitizers (PS) are targeted to disease tissue to reduce the dosage of PS and in addition to reduce the photo damage to the non-target tissue. We synthesized iron oxide nanoparticles (NP) armored with tumor targeting peptide and PS for targeted PDT."
Our news journalists obtained a quote from the research from Purdue University, "Chitosan covered Fe3O4 NPs (30 nm) were deposited with gold NPs to generate two distinct chemical surfaces. To the gold particles PS was attached with a lipoic acid linker. Human epidermal growth factor receptor (hEGFR)-specific peptide was also attached to the same particles via a nickel-nitrilotriacetic acid linker attached to the chitosan. Using these nanoparticles, peptide specific uptake and PDT mediated cell death of the SK-OV-3 cells (Her2(+) positive cells) were demonstrated by confocal microscopy, T-2 imaging and viability assays. Peptide mediated preferential distribution of these NPs into tumor tissue was also shown in a xenograft tumor model. After one intravenous injection and one PDT dose, peptide bound NPs retarded tumor growth significantly compared to dark controls or treatments with NPs without peptide. The tumor retardation by targeted NPs was achieved at a PS concentration of 3.9 nmol/animal, whereas similar effect was seen with free PS at 220 nmol/animal."
According to the news editors, the research concluded: "Therapeutic potential of these peptide containing NPs would be a useful in targeted PDT and in imaging the target tissue."
For more information on this research see: Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles. International Journal of Pharmaceutics, 2014;471(1-2):421-429. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news correspondents report that additional information may be obtained from A. Narsireddy, Purdue University, West Lafayette, IN 47907, United States. Additional authors for this research include K. Vijayashree, J. Irudayaraj, S.V. Manorama and N.M. Rao (see also Membrane Proteins).
Keywords for this news article include: Indiana, Therapy, Nanoparticle, United States, West Lafayette, Nanotechnology, Membrane Proteins, Peptide Receptors, Emerging Technologies, Growth Factor Receptors, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC